































































Differentiation of human pluripotent stem cells
to brain microvascular endothelial cell-like
cells suitable to study immune cell interactions
We describe the extended endothelial cell culture method (EECM) for the differentiation of
human pluripotent stem cells (hPSCs) into brain microvascular endothelial cell (BMEC)-like cells.
EECM-BMEC-like cells resemble primary human BMECs in morphology, molecular junctional
architecture, and diffusion barrier characteristics. A mature immune phenotype with proper
endothelial adhesion molecule expression makes this model distinct from any other hPSC-
derived in vitro BBB model and suitable to study immune cell migration across the BBB in a
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https://doi.org/10.1016/j.xpro.2021.100563SUMMARY
We describe the extended endothelial cell culture method (EECM) for the differ-
entiation of human pluripotent stem cells (hPSCs) into brain microvascular endo-
thelial cell (BMEC)-like cells. EECM-BMEC-like cells resemble primary human
BMECs in morphology, molecular junctional architecture, and diffusion barrier
characteristics. A mature immune phenotype with proper endothelial adhesion
molecule expression makes this model distinct from any other hPSC-derived in
vitro blood-brain barrier (BBB) model and suitable to study immune cell migra-
tion across the BBB in a disease relevant and personalized fashion.
For complete details on the use and execution of this protocol, please refer to
Lian et al. (2014), Nishihara et al. (2020a).BEFORE YOU BEGIN
Timing: 2 days to a week
For background information on the development of the protocol, please refer to (Lian et al., 2014)
for the endothelial progenitor cell (EPC) differentiation and (Nishihara et al., 2020a) for the Extended
Endothelial cell Culture Method (EECM)-BMEC-like cell differentiation.
1. Acquire all critical reagents mentioned in the key resources table.
2. Prepare all stock solutions listed below and make the necessary working aliquots.
3. Order the antibodies found in the key resources table for quality control.
4. Prepare media using recipes below, only when needed.
5. Acquire/thaw hPSCs and maintain as undifferentiated cultures in mTeSR based medium.
Cells need to be passaged at least twice before starting the differentiation.
Note: Both the hPSC maintenance and differentiation media are stable for up to 2 weeks at
4C.STAR Protocols 2, 100563, June 18, 2021 ª 2021 The Author(s).
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OPEN ACCESS ProtocolKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD31 Antibody, anti-human, FITC (clone AC128), (dilution 1:200)b Miltenyi Biotec Cat#130-117-390
APC-Cy7 Mouse Anti-Human CD31 (clone WM59), (0.5 mL/sample)f BD Biosciences Cat#563653
APC-Cy7 Mouse IgG1, k Isotype Control (clone MOPC-21),
(0.5 mL/sample)f
BD Biosciences Cat#557873
APC Mouse Anti-Human CD62E (clone 68-5H11), (2 mL/sample)f BD Biosciences Cat#551144
APC Mouse IgG1, k Isotype Control (clone MOPC-21), (2 mL/sample)f BD Biosciences Cat#555751
BV421 Mouse Anti-Human CD54 (clone HA58), (0.5 mL/sample)f BD Biosciences Cat#564077
BV421 Mouse IgG1, k Isotype Control (clone X40), (0.5 mL/sample)f BD Biosciences Cat#562438
BV510 Mouse Anti-Human CD62P (clone AC1.2), (2.5 mL/sample)f BD Biosciences Cat#743756
BV510 Mouse IgG1, k Isotype Control (clone X40), (2.5 mL/sample)f BD Biosciences Cat#562946
FITC Mouse Anti-human CD106 (clone 51-10C9), (20 mL/sample)f BD Biosciences Cat#551146
FITC Mouse IgG1, k Isotype Ctrl Antibody (clone MOPC-21),
(5 mL/sample)f
BioLegend Cat# 400108
PE Mouse Anti-Human CD102 (clone CBR-IC2/2), (4 mL/sample)f BD Biosciences Cat#558080
PE Mouse IgG2a kappa Isotype Control (clone eBM2a), (1 mL/sample)f Invitrogen Cat#12-4724-42
PE/Cyanine7 anti-human CD99 Antibody (clone 3B2/TA8),
(0.5 mL/sample)f
BioLegend Cat#371314
PE/Cyanine7 Mouse IgG2a, k Isotype Ctrl Antibody (clone MOPC-
173), (0.5 mL/sample)f
BioLegend Cat#400232
Anti-VE-cadherin antibody (clone F-8), (dilution 1:200), (fixative
MeOH)e
Santa Cruz Biotechnology Cat#sc-9989
Claudin 5 Monoclonal Antibody (clone 4C3C2), (dilution 1:200),
(fixative MeOH)e
Invitrogen Cat# 35-2500
Occludin Monoclonal Antibody (clone OC-3F10), (dilution 1:100),
(fixative MeOH)e
Invitrogen Cat#33-1500
Purified anti-human CD54 Antibody (clone HA58), (dilution 1:100),
(fixative n/a, live cell staining)e
BioLegend Cat#353102
Purified Mouse Anti-Human CD106 (clone 51-10C9), (dilution 1:100),
(fixative n/a, live cell staining)e
BD Biosciences Cat#555645
Actin, Smooth Muscle Ab-1, Mouse Monoclonal Antibody (clone 1A4),
(dilution 1:200), (fixative 1% PFA)e
Fisher Scientific Cat#MS113P
Monoclonal Anti-Calponin antibody produced in mouse (clone hCP),
(dilution 1:15000), (fixative 1% PFA)e
Sigma-Aldrich Cat#C2687
Anti-TAGLN/Transgelin (polyclonal), (dilution 1:1000), (fixative 1%
PFA)e
Abcam Cat#ab14106
Cy3 AffiniPure F(ab’) Fragment Goat Anti-Mouse IgG, F(ab’)2 fragment
specific, (dilution 1:200)e
Jackson ImmunoResearch Cat#115-166-006
Cy3 AffiniPure Donkey Anti-Rabbit IgG (H+L), (dilution 1:200)e Jackson ImmunoResearch Cat#711-165-152
Chemicals, peptides, and recombinant proteins
AbC Total Antibody Compensation Bead Kitf Invitrogen Cat#A10497
Accutaseb,c Sigma-Aldrich Cat#A6964-500ml
Acetic acidb,c Sigma-Aldrich Cat#695092
Advanced D-MEM/F-12b Life Technologies Cat#12634
B-27 Supplement (503), serum freeb,c Thermo Fischer Scientific Cat#17504044
Bovine serum albumin (BSA), 7.5% in dPBSb,c Sigma-Aldrich Cat#A8412-100ml
CellTracker Green CMFDA Dyeg Invitrogen Cat#C7025
CHIR99021b Selleck Chemicals Cat#S1263
Collagen IV from human placentac Sigma-Aldrich Cat#C5533
DAPI (40,6-Diamidino-2-Phenylindole, Dilactate), (concentration
1 mg/mL), (fixative PFA/MeOH)e
Invitrogen Cat#D3571
Dimethylsulfoxide (DMSO), sterileb,c Sigma-Aldrich Cat#D2650
DMEM (13), [+] 4.5 g/L D-glucose, [-] L-glutamine, [-] pyruvateg Thermo Fischer Scientific Cat#31053-028
Dulbecco’s modified Eagle’s medium/nutrient mixture F-12
(DMEM-F12)a,b,c
Thermo Fischer Scientific Cat#11320074
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Dulbecco’s (d) PBS (without calcium, magnesium)b Thermo Fisher Cat#14190250
EasySepFITC Positive Selection Kit IIb STEMCELL Technologies Cat#18558
Fetal Bovine Serum, qualifiedb,c Thermo Fischer Scientific Cat#10270106
Fibronectin from bovine plasmac Sigma-Aldrich Cat#F1141
Ficoll-Paque PLUSg Sigma-Aldrich Cat#GE17144002
Fluorescein sodium saltd Sigma-Aldrich Cat#F6377
GlutaMAX Supplementb Thermo Fischer Scientific Cat#35050-061
Glutaraldehyde solutiong Sigma-Aldrich Cat#G6257
HCLe Sigma-Aldrich Cat#H1758
HEPES buffer solutiong Thermo Fischer Scientific Cat#15630-056
Hoechst 33342 Solution, (concentration 4 mM)e Fisher Scientific Cat#PI62249
Human Endothelial SFM (hESFM)b,c Thermo Fischer Scientific Cat#11111-044
Human fibroblast growth factor 2b,c Tocris Cat#233-FB-500
Kanamycin Sulfate (1003)g Thermo Fischer Scientific Cat#15160-047
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrateb Sigma-Aldrich Cat#A8960-5G
L-Glutamine 200 mM (1003)g Thermo Fischer Scientific Cat#25030-024
Matrigel, growth factor reduceda,b Corning Cat#354230
MEM NEAA (1003)g Thermo Fischer Scientific Cat#11140-035
Methanole Sigma-Aldrich Cat#32213
Mowiole Sigma-Aldrich Cat#81381
mTeSR1 complete kit (basal medium plus 53 supplement) a,b STEMCELL Technologies Cat#85850
NaCle Sigma-Aldrich Cat#71376
Paraformaldehydee Millipore Cat#104005
Pen Strepg Thermo Fischer Scientific Cat#15140-122
Recombinant Human IFN-gamma Proteine,f,g R&D Systems Cat#285-IF-100
Recombinant Human IL-2g BD Biosciences Cat#554603
Recombinant Human TNF-alpha Proteine,f,g R&D Systems Cat#210-TA-020
Recombinant Human VEGF165c PeproTech Cat#100-20
ROCK inhibitor Y-27632a,b,c Tocris Cat#1254
RPMI medium 1640g Thermo Fischer Scientific Cat#21875-034
Skim milke BD Biosciences Cat#232100
Sodium azide (NaN3)
e Sigma-Aldrich Cat#71290
Sodium pyruvateg Thermo Fischer Scientific Cat#11360-039
Tris basee Sigma-Aldrich Cat#93362
Triton X-100e Sigma-Aldrich Cat#X100
Versenea Thermo Fischer Scientific Cat#15040-066
Water, sterile, cell culturec Sigma-Aldrich Cat#W3500
Experimental models: Cell lines
iPS(IMR90)-4 human induced pluripotent stem cells WiCell RRID:CVCL_C437
H9 (WA09) human embryonic stem cells WiCell RRID:CVCL_9773
Other
0.22 mm Syringe filter TPP Cat#99722
40 mm Falcon cell strainerb Falcon Cat#352340
5 mL Round-bottom tubeb SPL Cat#40005
15 mL Centrifuge tube Biofil Cat#CFT011500
50 mL Centrifuge tube Biofil Cat#CFT011150
50 mL Centrifuge tube (fit for 40 mm Falcon cell strainer)b nerbe plus Cat#02-572-8001
96-Well plate, round bottomf SPL Cat#34096
Chamber slidese,g Thermo Fischer Scientific Cat#178599
Corning tissue culture plates (6-well) Corning Cat#3506
Corning tissue culture plates (12-well) Corning Cat#3512
Corning tissue culture plates (24-well) Corning Cat#3526
Corning tissue culture plates (96-well) Corning Cat#3596
Cryo Tube 20c TPP Cat#89020
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
EasySepMagnetb STEMCELL Technologies Cat#18000
PLAQUE EN VERRE 12 CAVITES D 16MMd,e MMS Cat#10489011
Scalpeld,e FEATHER Cat#2975-11
Transwells, PC Membrane, 0.4 mm, 12 mm, TC-Treatedd,e Corning Cat#3401
aindicates reagents use for hPSCs thawing and maintenance (section 1–3 of protocol).
bindicates reagents use for EPC differentiation (section 4–6 of protocol).
cindicates reagents use for EECM-BMEC like cell differentiation (section 7–12 of protocol).
dindicates reagents use for measuring sodium fluorescein permeability (section 13 of protocol).
eindicates reagents use for immunofluorescence staining (section 14 of protocol).
findicates reagents use for flow cytometry analysis (section 15 of protocol).
gindicates reagents use for T-cell adhesion assay (section 16 of protocol).
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OPEN ACCESS ProtocolMATERIALS AND EQUIPMENT
We recommend against the use of antibiotics in culture and differentiation of hPSCs. Pay close atten-
tion to working at sterile conditions. Buy sterile centrifuge tubes, microcentrifuge tubes, and pipet
tips or autoclave before use. Prepare medium under sterile and endotoxin-free conditions. If some
materials are not sterile, use 0.22 mm syringe filters for sterile filtration.mTeSR1 medium (commercially available mTeSR1 complete kit) Final concentration Amount
Basal medium n/a 400 mL
5 3 supplement provided from mTeSR1 complete kit 1 3 100 mL










CRITICAL: Store mTeSR1 medium at 2C–8C for up to 2 weeks or 20C for up to
6 months. Avoid warming the medium for extended periods of time in the 37C water
bath, because bFGF is unstable at this temperature.trigel stock solution aliquot Final concentration Amount
trigel, growth factor reduced 2.5 mg depends on lot
al n/a depends on lot, approximately 250 mLCRITICAL: Matrigel is sensitive to temperature. Place Matrigel at least 8 h at 4C for thaw-
ing. Pre-chill pipet tips that fit a 1000 microliter pipette and microcentrifuge tubes at
20C. When aliquoting Matrigel, place Matrigel and microcentrifuge tubes on ice within
the biosafety cabinet. Store aliquots at 20C up to 6 months. The Matrigel concentration
varies from lot to lot. Consult themanufacturer’s datasheet to calculate the precise volume
of the aliquot containing 2.5 mg Matrigel.an fibroblast growth factor 2 (bFGF/FGF2) stock solution Final concentration Amount
an fibroblast growth factor 2 100 mg/mL 500 mg
becco’s (d) PBS n/a 5 mL
ine serum albumin (BSA), 7.5% in dPBS 0.1% 66.7 mL






















OPEN ACCESSProtocolCRITICAL: Make 20–200 mL aliquots (depending on the amount you anticipate to be usingwithin 1 month) and store aliquots at 20C for up to 3 months. Keep a single working
aliquot of stock solution at 4C up to 1 month. Avoid freezing-thawing cycles.CK inhibitor (Y-27632) stock solution Final concentration Amount
CK inhibitor Y-27632 10 mM 10 mg
ter, sterile, cell culture n/a 2.9561 mL
al n/a 2.9561 mLCRITICAL: Make 100–200 mL aliquots (depending on the amount you anticipate usingwithin 2 months) and store aliquots at 80C for up to 1 year. Keep a single working
aliquot of stock solution at 4C up to 2 months. Avoid freezing-thawing cycles.scorbic acid stock solution Final concentration Amount
scorbic acid 2-phosphate sesquimagnesium salt hydrate 100 mg/mL 5 g
ter, sterile, cell culture n/a 50 mL
al n/a 50 mLCRITICAL: Make 1 mL aliquots and store at 20C for up to 1 year. If L-ascorbic acid dose
not easily dissolve, place 50 mL tube containing L-ascorbic acid and sterile water on the
rotator at 4C until completely dissolved before making aliquots.IR99021 stock solution Final concentration Amount
IR99021 10 mM 10 mg
ethylsulfoxide (DMSO), sterile n/a 2.1490 mL
al n/a 2.1490 mLCRITICAL: Make 100–200 mL aliquots (depending on the amount you anticipate usingwithin 1 month) and store aliquots at 20C up to 1 year. Keep a single working aliquot
of stock solution at 4C up to 1 month. Avoid freezing-thawing cycles.tic acid, 0.5 mg/mL solution Final concentration Amount
tic acid 0.5 mg/mL 119 mL
ter, sterile, cell culture n/a 250 mL
al n/a ~250 mLCRITICAL: Filter sterilize and store at 4Clagen IV for filter coating Final concentration Amount
lagen IV from human placenta 1 mg/mL 5 mg
tic acid, 0.5 mg/mL solution n/a 5 mL



























ProtocolCRITICAL: Allow to dissolve at least 4 h at 4C before using and storing at 4C. Collagen IV
dissolved in acetic acid is used for Transwell filter coating.lagen IV for tissue culture plate coating Final concentration Amount
lagen IV from human placenta 1 mg/mL 5 mg
ter, sterile, cell culture n/a 5 mL
al n/a 5 mLCRITICAL: Allow to dissolve at least 4 h at 4C. Make 300 mL aliquots and store at 20C.
Collagen IV dissolved in water is used for tissue culture plate coating.Alternatives: Collagen IV dissolved in acetic acid can be used for tissue culture plate coating.:5 collagen IV/fibronectin/water coating solution Final concentration Amount (per Transwell filter)
lagen IV for filter coating 400 mg/mL 80 mL
ronectin from bovine plasma 100 mg/mL 20 mL
ter, sterile, cell culture n/a 100 mL
al n/a 200 mLCRITICAL: Prepare 4:1:5 collagen IV/fibronectin/water coating solution just before use.Coat Transwell filters (PC Membrane, 0.4 mm, 12 mm, TC-Treated, Costar 3401) at least
4 h at 37C before using. We recommend incubating coated filters more than 8 h.R basal medium Final concentration Amount
anced D-MEM/F-12 n/a 500 mL
taMAX Supplement n/a 6.25 mL
scorbic acid stock solution (100 mg/mL) n/a 305 mL
al n/a ~500 mLCRITICAL: Store LaSR basal medium at 2C–8C for up to 2 weeks.EM/F-12-10 medium Final concentration Amount
becco’s modified Eagle’s medium/nutrient mixture F-12 (DMEM-
)
n/a 450 mL
al Bovine Serum, Qualified 10% 50 mL
al n/a 500 mLCRITICAL: Store DMEM/F-12-10 medium at 2C–8C up to 1 month.w buffer-1 Final concentration Amount
becco’s (d) PBS n/a 467 mL
ine serum albumin (BSA), 7.5% in dPBS 5 mg/mL 33.3 mL



























OPEN ACCESSProtocolCRITICAL: Store Flow buffer-1 at 2C–8C up to 6 months.SR medium Final concentration Amount
an Endothelial SFM (hESFM) n/a 98 mL
7 Supplement (503), serum free 1 3 2 mL
an fibroblast growth factor 2 (bFGF/FGF2) stock solution (100 mg/
)
20 ng/mL 20 mL
al n/a ~100 mLCRITICAL: Store hECSR medium at 2C–8C up to 2 weeks.ezing medium for EPCs, EECM-BMEC-like cells and SMLCs Final concentration Amount
SR medium n/a 30 mL
al Bovine Serum, Qualified 30% 15 mL
ethylsulfoxide (DMSO), sterile 10% 5 mL
CK inhibitor (Y-27632) stock solution 5 mM 25 mL
al n/a ~50 mLCRITICAL: Store Freezing medium at 2C–8C up to 2 weeks.F stock solution Final concentration Amount
ombinant Human VEGF165 100 mg/mL 10 mg
ter, sterile, cell culture n/a 100 mL
al n/a 100 mLCRITICAL: Make 5 mL aliquots and store at 20C up to 1 year. Keep a single working
aliquot of stock solution at 4C up to 1 week. Avoid freezing-thawing cycles.Fa stock solution Final concentration Amount
ombinant Human TNF-alpha Protein 100 mg/mL 20 mg
becco’s (d) PBS n/a 200 mL
ine serum albumin (BSA), 7.5% in dPBS 0.1% 2.667 mL
al n/a ~203 mLCRITICAL: Make 5 mL aliquots and store at 80C up to 3 months. Keep a single working
aliquot of stock solution at 4C up to 1 week. Avoid freezing-thawing cycles.g stock solution Final concentration Amount
ombinant Human IFN-gamma Protein 200 mg/mL 100 mg
becco’s (d) PBS n/a 500 mL
ine serum albumin (BSA), 7.5% in dPBS 0.1% 6.667 mLCRITICAL: Make 5–10 mL aliquots and store at 80C up to 3 months. Keep a single work-
Total n/a ~507 mLing aliquot of stock solution at 4C up to 1 week. Avoid freezing-thawing cycles.STAR Protocols 2, 100563, June 18, 2021 7
Tris-Buffered Saline (TBS) 13 Final concentration Amount
Tris Base 50 mM 6.05 g
NaCl 150 mM 8.76 g
HCl n/a
distilled water n/a ~1000 mL





























ProtocolCRITICAL: To prepare, dissolve Tris Base and NaCl in 800 mL of distilled water. Adjust pHto 7.4 with HCl and make volume up to 1000 mL with distilled water. TBS is stable at 4C up
to 3 months.cking buffer Final concentration Amount
milk 5% (w/v) 5 g
-Buffered Saline (TBS) 13 n/a 100 mL
on X-100 0.3% (v/v) 300 mL
3, 10% solution in water 0.04% (v/v) 400 mL
al n/a ~100 mLCRITICAL: Make 10 mL aliquots and store at20C up to 6 months. Keep a single working
aliquot of stock solution at 4C up to 2 weeks.S buffer Final concentration Amount
becco’s (d) PBS n/a 500 mL
al Bovine Serum, Qualified 2.5% 10 mL
3, 10% solution in water 0.1% 5 mL
al n/a 515 mLCRITICAL: Store buffer at 2C–8C up to 6 months.ium fluorescein stock solution Final concentration Amount
becco’s (d) PBS n/a 2.6577 mL
orescein sodium salt 10 mM 10 mg
al n/a 2.6577 mLCRITICAL: Make 50 mL aliquots and store at 20C up to 2 years. Store at 2C–8C in the
dark up to 6months. To make working concentration, dilute 1:1000 in hECSRmedium (final
concentration 10 mM). Sodium fluorescein is light sensitive. Avoid exposure to light.ell medium Final concentration Amount
I Medium 1640 n/a 82.8 mL
ium Pyruvate 1% 1 mL
M NEAA (1003) 1% 1 mL
amycin Sulfate (1003) 1% 1 mL
lutamine 200 mM (1003) 1% 1 mL
Strep 1% 1 mL
al Bovine Serum, Qualified 10% 10 mL
ombinant Human IL-2 500 units/mL depends on lot
al n/a ~100 mL

















OPEN ACCESSProtocolCRITICAL: Store T-cell medium at 2C–8C up to 1 week. Recombinant human IL-2 manu-
facturer instructions (https://www.bdbiosciences.com/ds/pm/tds/554603.pdf) report an
activity range of 0.06–1.0 3 109 units/mg. The concentration of recombinant human IL-2
in the culture medium must be optimized depending on the T cell subset (e.g., naı̈ve
T cell, activated T cell) of your interest.ell wash buffer Final concentration Amount
ell medium 10% 10 mL
I Medium 1640 n/a 87.5 mL
ES Buffer Solution 25 mM 2.5 mL
al n/a 100 mLCRITICAL: Store T-cell wash buffer at 2C–8C up to 1 week.ration assay medium Final concentration Amount
EM (13), [+] 4.5 g/L D-Glucose, [-] ʟ-Glutamine, [-] Pyruvate n/a 90.5 mL
ES Buffer Solution 25 mM 2.5 mL
al Bovine Serum, Qualified 5% 5 mL
lutamine 200 mM (1003) 2% 2 mL
al n/a 100 mLCRITICAL: Store migration assay medium at 2C–8C up to 1 week.lTracker Green CMFDA Dye stock solution Final concentration Amount
lTracker Green CMFDA Dye 3 mM 50 mg
ethylsulfoxide (DMSO), sterile n/a 36 mL
al n/a 36 mLCRITICAL:Make 3 mL aliquots and store at20C up to 1 year. Tomake a working solution,
dilute 1:3000 in migration assay medium (final concentration 1 mM). CMFDA is light sensi-
tive. Avoid exposure to light.STEP-BY-STEP METHOD DETAILS
Preparing hESC/hiPSC cultures for endothelial progenitor cell (EPC) differentiation
Timing: 10–14 days
This step describes the expansion of hPSC lines for producing healthy colonies of human embryonic
stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) suitable for endothelial progen-
itor cell (EPC) differentiation. hPSCs are cultured under feeder-free conditions and passaged when
reaching 80% confluency. hPSCs are passaged at least twice or cultured 2 weeks before starting the
EPC differentiation.
Timing: 1–1.5 h
This step describes the preparation of Matrigel-coated 6-well plates for hPSC culture. This Matrigel
coating procedure is also used to prepare plates for use in hPSC differentiation.
1. Prepare Matrigel-coated 6-well plates before starting the hPSC culture.STAR Protocols 2, 100563, June 18, 2021 9
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OPEN ACCESS Protocola. Add 30 mL cold DMEM/F-12 to a 50 mL tube. Using a micropipette, remove 1 mL of DMEM/F-
12.
b. Using 1 mL of DMEM/F-12, pipet up and down to thaw and dissolve a Matrigel aliquot (con-
taining 2.5 mg Matrigel).
c. Add thawed Matrigel to the 50 mL tube, containing 29 mL cold DMEM/F-12.
d. Add 1 mL of the resulting Matrigel solution to each well of the 6-well plates.
e. Agitate each plate to ensure coverage of the complete bottom of each well with Matrigel so-
lution and place in incubator (37C, 5% CO2) for at least 1 h.
Note: If all Matrigel-coated wells will not be needed immediately for culture, add 1 mL
DMEM/F12 instead to the wells not needed and store in incubator (37C, 5% CO2) up to
1 week.
Timing: 30–60 min
This step describes the method of thawing hPSC lines. If hPSCs are in continuous culture in your lab-
oratory, skip this step and proceed directly to step 3.
2. Thaw hESC/hiPSC lines.
a. Prepare a 15 mL centrifuge tube containing 4 mL mTeSR1 medium at 20C–25C.
b. Thaw 1 vial of cryopreserved hESCs/hiPSCs by rapidly rubbing the tube between your hands
or swirling it in a 37C water bath until there is only a small piece of ice remaining.
c. Slowly add 500 mL of mTeSR1 medium to the cryotube and gently pipet up and down once to
completely thaw hPSCs, then slowly transfer hPSCs to the centrifuge tube containing mTeSR1
medium.
Note: At the first signs of thawing, hPSCs should immediately be transferred into 15 mL tube
containing 4 mL of mTesR1 medium to reduce cryopreservation-mediated damage to the cell
membranes.
CRITICAL: Avoid singularization of the hPSCs as hPSCs will attach and survive better ifmaintained as cell clumps.10d. Centrifuge hPSCs at 200 g, 5 min, at 20C–25C. While hPSCs are centrifuging, label a Matri-
gel-coated plate with the name of the cell line, passage number, and passage date.
e. Remove the supernatant and carefully resuspend the pellet in 2 mL of mTeSR1 medium +
10 mM ROCK inhibitor Y-27632 (add ROCK inhibitor stock solution at 1:1000) per well of a
6-well plate. Aspirate Matrigel coating solution from the 6-well plate and seed the hPSCs sus-
pension onto Matrigel-coated wells.
Note: Consult documentation from the source of hESCs/hiPSCs for the recommended num-
ber of wells one vial should be thawed into.
CRITICAL: Avoid too intense resuspension as hPSCs will better attach and survive if main-tained as cell clumps.f. Transfer 6-well plate into the incubator (37C, 5% CO2) and gently move the plate back and
forth and from side to side on the incubator shelf to evenly distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is impor-
tant to place the plate onto the incubator shelf first and move the plate using the shelf as sup-
port inside the incubator.
g. One day later, remove ROCK inhibitor Y-27632 by replacing medium in each well with 2 mL of
mTeSR1 medium.STAR Protocols 2, 100563, June 18, 2021
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OPEN ACCESSProtocolTiming: 3–7 days (when you use hPSCs already thawed previously)
Timing: 2–3 weeks (when you use freshly thawed hPSCs)
This step describes the maintenance of hPSCs, which is essential before starting EPC differentiation.
3. Maintenance of hPSCs (passage before start of differentiation)
a. Change mTeSR1 medium every day to reduce probability of spontaneous differentiation.Note: Because the proliferation rate is hPSC line-dependent, hPSCs will be ready for the first
passage in 4–7 days.
b. Once hPSCs reach approximately 80% confluency, typically when individual colonies begin to
touch, prepare a Matrigel-coated 6-well plate for passaging.
c. Aspirate medium from one well of hPSCs, wash hPSCs with 1 mL Versene, and subsequently
aspirate Versene from well.
d. Add 1 mL of Versene to the well of hPSCs. Incubate at 37C, 5% CO2 in the incubator for 4–
7 min, depending on cell line.
e. While hPSCs are dissociating, label a newMatrigel-coated plate with the name of the cell line,
passage number, passage date, and split ratio (usually 1:6 ratio). Aspirate Matrigel coating so-
lution from 3 wells and add 1 mL of mTeSR1 medium per well of the 6-well plate.
f. Prepare a 15 mL centrifuge tube containing 2 mL of mTeSR1 medium at 20C–25 C.
g. Observe the detachment process of the hPSCs under the microscope. Once hPSCs start to
detach (Methods video S1), remove Versene and dissociate hPSCs by vigorously pipetting
2 mL of mTeSR1 medium.
Note: If hPSCs do not detach well, gently scrape hPSCs using the tip of a 5 mL pipet and pi-
petting mTeSR1 over the hPSCs again. Gentle scraping yields larger clumps of hPSCs than
prolonged Versene treatment, which may improve hPSC maintenance.
h. Collect 1 mL of the resulting hPSCs suspension in mTeSR1 medium and transfer to the 15 mL
conical tube containing 2 mL of mTeSR1 medium.
i. Distribute 1 mL of hPSC suspension into each well of the plate prepared in step ‘‘e’’ (for a total
volume 2 mL per well). In this way, hPSCs are passaged at a 1:6 ratio.
Note: Split ratio may need to be optimized for individual hPSCs lines or based on the hPSC
number needed for EPC differentiation.
j. Transfer 6-well plate into the incubator (37C, 5% CO2) and gently move the plate back and
forth and from side to side on the incubator shelf to evenly distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.
k. If using a newly thawed hPSC line, maintain hPSC in culture and passage at least once more
before initiating an EPC differentiation. This allows hPSCs recover from freezing.
CRITICAL: Usually the newly passaged hPSCs reach 80% confluency in 4–7 days. If it takeslonger, the risk of spontaneous differentiation increases. In this case, we recommend
increasing split ratio.CRITICAL: Make sure that the hPSC cultures used for EPC differentiation (section ‘‘differ-entiation hPSCs into endothelial progenitor cells (EPCs)’’) lack spontaneous cell differenti-
ation events. To eliminate cells that have undergone spontaneous differentiation, either (i)
passage undifferentiated hPSC colonies by picking colonies using a sterile pipette tip or (ii)STAR Protocols 2, 100563, June 18, 2021 11
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OPEN ACCESS Protocoltreat cultures with Versene for a reduced time (2–3 min) as explained in step ‘‘d,’’ which
often facilitates selective detachment of hPSC colonies while spontaneously differentiated
cells remain attached to the plate. For the details on the maintenance of hPSC colonies,
please refer to manufacturer’s instructions (https://cdn.stemcell.com/media/files/
manual/10000005505-Maintenance_of_Human_Pluripotent_Stem_Cells_mTeSR1.pdf?
_ga=2.138301808.1976489461.1615541621-432292338.1615280857).Differentiation of hPSCs into EPCs
Timing: 9 days
This step describes the differentiation of hPSC lines into endothelial progenitor cells (EPCs). For
background information on the development of the protocol, please refer to Nishihara et al.
(2020a), Baoet al. (2016), and Lian et al. (2014).
Timing: 3 days
This step describes the first phase of the EPC differentiation protocol: seeding and expansion of
hPSCs prior to EPC differentiation.
4. Singularized hPSC seeding and expansion for CD31+CD34+ EPC differentiation (Day -3 – Day -1)
a. Initiate differentiation once hPSC colonies reach 80% confluency (Figure 1).
b. Prepare Matrigel-coated 12-well plates using the method in step 1, except use 0.5 mL of Ma-
trigel solution per well of each 12-well plate. Incubate at least 1 h at 37C.
c. Aspirate mTeSR1 medium from one well of hPSCs in a 6-well plate.12Note: Typically, we collect hPSCs from one well of 6-well plate (2.5 – 3.5 3106 cells) for
differentiation.
d. Add 1 mL Accutase to the well and incubate at 37C until all the hPSCs have completely de-
tached (approximately 7 min).
e. Using a micropipette, collect hPSCs, and pipette gently over surface 2–3 times to dislodge
any remaining hPSCs and obtain a single cell suspension. Transfer hPSCs into a 15 mL centri-
fuge tube containing 4 mL of mTeSR1 medium.
f. Resuspend well and take 10 mL of the hPSC suspension and pipet into a Neubauer Chamber.
g. Centrifuge hPSCs for 5 min at 200 g, at 20C–25 C.
h. Count hPSCs on Neubauer Chamber and calculate appropriate volume of cells to add to each
12-well plate (range 75–400 3103 hPSCs per well of a 12-well plate).
Note: We recommend seeding at least 6 wells of a 12-well plate for EPC differentiation.
CRITICAL: The seeding density must be optimized for each individual hPSC line and foreach passage number depending on the growth rate of the hPSCs. When using a hPSC line
for the first time, we recommend seeding at several different seeding densities (e.g.,
75 3103, 100 3103, 200 3103, 400 3103 hPSCs per well of a 12-well plate) and evaluating
the resulting yield of CD31+ EPCs.i. After centrifuging down the hPSCs, remove the supernatant and resuspend the pellet in 1 mL
of mTeSR1.
j. Add appropriate volume of hPSCs calculated in step ‘‘h’’ to each well of a 12-well plate con-
taining 1 mL mTeSR1 + 10 mM ROCK inhibitor Y-27632 (add ROCK inhibitor stock solution at
1:1000).
k. Transfer 6-well plate into the incubator (37C, 5% CO2) and gently move the plate back and
forth and from side to side on the incubator shelf to evenly distribute the cells.STAR Protocols 2, 100563, June 18, 2021
Figure 1. Protocol overview
Schematic of protocol steps, typical brightfield image of cells, and snapshot of medium color during differentiation is shown. Scale bar = 100 mm.
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OPEN ACCESSProtocolNote: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.
l. Approximately 24 h later (i.e., Day -2), removemTeSR1 + ROCK inhibitor and replacemedium
with 2 mL of mTeSR1 medium per well.
Note: Stem cells treated with the ROCK inhibitor should have a mesenchymal morphology
(Figure 1).
m. Approximately 24 h later (i.e., Day -1), replacemediumwith 2mL of mTeSR1medium per well.
Note: After withdrawal of the ROCK inhibitor, hPSCs should regain their typical hPSC
morphology of tightly packed cells with well-defined edges (Figure 1).
CRITICAL: Seeding density of hPSCs at Day -3 is critical for successful EPC differentiation.Seeding density needs to be optimized for each hPSC line, as well as for each passage. For
example, seeding 75–100 3103 hPSCs per well of a 12-well plate works well for theSTAR Protocols 2, 100563, June 18, 2021 13
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400 3103 hPSCs per well of a 12-well plate (20–100 3103/cm2).Timing: 6 days
This step describes the second phase of the EPC differentiation protocol. Briefly, mesoderm differ-
entiation is initiated by adding the GSK3 inhibitor for 2 days, and the cells are subsequently
expanded for 3 days.
5. Endothelial progenitor differentiation with GSK3 inhibitor CHIR99021 (Day 0–Day 5)
a. At Day 0, prepare LaSR basal medium supplemented with 8 mMCHIR99021 and allow to warm
to 20C–25 C. RemovemTeSR1 and add 2mL of LaSR basal medium supplemented with 8 mM
CHIR99021 to each well of 12-well plate.
b. At Day 1, aspirate the medium and replace with 2 mL of LaSR basal medium supplemented
with 8 mM CHIR99021 at 20C–25C.
c. At Day 2, 3, and 4, aspirate the medium and replace with 2 mL of LaSR basal medium (without
CHIR99021) prewarmed to 20C–25C.
CRITICAL: hPSCs should be confluent by Day 1, or at the latest Day 2 (Figure 1). If thehPSCs do not reach confluency by Day 2, the differentiation usually fails. In this case, we
recommend increasing the seeding density of hPSCs.14CRITICAL: If many cells are detached from the surface at Day 3–Day 5, we recommenddecreasing the initial hPSCs seeding density. See troubleshooting problem 1.CRITICAL: Though we identified 7–8 mM CHIR99021 is optimal for the hPSC lines that wetested, other hPSC lines may respond to CHIR99021 treatment differently. Therefore opti-
mization of CHIR99021 concentration may be required.CRITICAL: The effect of CHIR99021 may change between different lots, therefore theCHIR99021 concentration should be validated when switching the CHIR99021 lot.Timing: 3–4 h
This step describes the final phase of the EPC differentiation protocol: purification of EPCs byMACS.
6. Purification of EPCs by magnetic activated cell sorting (MACS) using positive selection for FITC-
labeled CD31+ cells.
a. At Day 5, aspirate themedium, add 1mLAccutase to each well, and incubate at 37C, 5%CO2
in the incubator for 6–8 min.
b. Pipette 5–10 times with a micropipette to obtain a single-cell suspension and then filter the
cell suspensions through a 40 mm Falcon cell strainer into a 50 mL Centrifuge tube containing
12 mL DMEM/F-12-10 medium.Note: We use 50 mL Centrifuge tube from nerbe plus because the diameter fits well to the
40 mm Falcon cell strainer.
c. Fill DMEM/F-12-10 medium up to 50 mL to stop Accutase reaction, resuspend cells and take
10 mL of the cell suspension and place onto Neubauer Chamber.
Note: If you use more than two 12-well plates (more than 24 mL of Accutase), transfer cell
suspension into two 50 mL tubes.
d. Centrifuge the cells at 200 g for 5 min at 20C–25C.
e. Count cell number.STAR Protocols 2, 100563, June 18, 2021
Figure 2. Flow cytometry analysis of pre-MACS and post-MACS sorted cells at day 5 of EPC differentiation
Samples were examined for the fraction of CD31+ cells using a flow cytometer.
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OPEN ACCESSProtocolf. After centrifugation, aspirate the supernatant and add 15 mL DMEM/F-12-10 medium to re-
suspend the pellet. Transfer the resulting cell suspension into a fresh 15 mL centrifuge tubes.
g. Centrifuge the cells at 200 g for 5 min at 20C–25C.
h. Aspirate the supernatant and resuspend the cell pellets at a concentration of 13 107 cells per
100 mL Flow Buffer-1.
i. Add 1:100 of FcR blocking reagent (provided from EasySep FITC Positive Selection Kit II) and
incubate for 5 min.
j. Add 1:200 of FITC-conjugated CD31 antibody.
Note: Manufacturer recommends 1:50 dilution for FITC-conjugated CD31 antibody without
providing antibody concentration, however we have found that 1:200 dilution works as well.
You may need to adjust appropriate dilution of FITC-conjugated anti-CD31 antibody de-
pending on lot number (range from 1:50 -1:400).
k. Incubate the mixture in the dark at 20C–25C for 30 min.
l. After incubation, add 10mLFlowBuffer-1 and take a 10mL sample toperform flow cytometry anal-
ysis (Figure 2) and centrifuge the remaining cell suspension at 200 g for 5 min at 20C–25C.
Note: If you cannot perform flow cytometry analysis immediately, store the sample for flow
cytometry at 4C until finished with the MACS.
CRITICAL: It is recommended that the pre-sort cell mixture contain more than 10% ofCD31+ EPCs before proceeding to MACS. If the EPC percentage is less than 6%, optimize
initial seeding density and/or CHIR99021 concentration.m. Aspirate the supernatant, resuspend the cell pellet at a concentration of 1 3 107 cells per
100 mL Flow Buffer-1, and add EasySep FITC Selection Cocktail at 5 mL per 100 mL antibody
labeled cell suspension. Resuspend well and incubate at 20C–25C for 15 min.
n. Vortex Magnetic Nanoparticles and add Magnetic Nanoparticles at 5 mL per 100 mL cell sus-
pension, resuspend well by pipetting and incubate at 20C–25C for 10 min.
o. Bring the cell suspension to a total volume of 2.5 mL Flow Buffer-1, resuspend the cells, and
then transfer into a 5 mL round-bottom flow cytometry tube.
p. Place the flow cytometry tube (without cap) into the magnet and incubate for 5 min.
q. Pick up the magnet, and in one continuous motion invert the magnet and flow tube, pouring
off the supernatant fraction, containing FITC-CD31 antibody unlabeled cells. Leave the mag-
net and tube inverted for 2–3 s allowing supernatant drop off, remove the drop at the edge of
the tube by careful aspiration with a Pasteur pipet attached to a vacuum pump, then return




ProtocolCRITICAL: The EasySep manufacturer’s instructions (https://cdn.stemcell.com/media/files/pis/DX22365-PIS_1_0_0.pdf?_ga=2.180300580.1448779528.1614351881-737646090.1614351881)
do not recommend shaking or blotting off any drops that may remain hanging from the
mouth of the tube, however we have found that careful aspiration of these last drops in-
creases EPC purity after MACS.r. Remove the flow cytometry tube, containing the CD31+ cells from the magnet, add 2.5 mL
FlowBuffer-1, and resuspend the cell suspension by gently pipetting up and down 2–3 times.
s. Place the flow tube back into the magnet and incubate for 5 min.
t. Repeat steps ‘‘q–s’’ three times and then step ‘‘q’’ once more (for a total of 4 washes).
u. Remove the flow cytometry tube from the magnet and resuspend the purified CD31+ cells in
an appropriate amount of desired medium (hECSR for extended EC culture or Freezing me-
dium for freezing).
v. Resuspend CD31+ cells and take a 10 mL sample of cell suspension for counting.
w. Take an additional 10 mL sample of cell suspension for flow cytometry analysis. Use a flow cy-
tometer to assess the percentage of CD31+ cells in the pre-MACS (step ‘‘l’’) and post-MACS
samples (Figure 2).
CRITICAL: For successful selective EC passaging described below, we recommendedpost-MACS purity of > 95%. If the purity is low, see troubleshooting problem 2.Extended endothelial cell culture method to differentiate brain microvascular endothelial
cell-like cells (EECM-BMEC-like cells) and smooth muscle-like cells (SMLCs)
Timing: 10–15 days
This step describes the culture of EPCs and induction of BMEC-like cells by the extended endothelial
cell culture method, as well as SMLC culture and preparation of SMLC-derived conditioned medium
(CM). SMLCs are a biproduct of EECM-BMEC-like cell differentiation and their co-culture or the CM
derived from SMLCs is essential to achieve optimal VCAM-1 expression on EECM-BMEC-like cells.
Timing: 30–60 min
This step describes the preparation of collagen IV coated plates for the EECM-BMEC-like cell
culture.
7. Prepare 10 mg/ml collagen IV (Collagen IV for tissue culture plate coating)-coated 6-well plate
a. Dilute a 300 mL aliquot of collagen IV (1 mg/mL) in 30 mL sterile water (Water, sterile, cell cul-
ture from Sigma) and add 1 mL of the colloidal solution to each well of the 6-well plates. Incu-
bate plates with collagen IV for at least 30 min at 37C and for up to 1 week.
Timing: 3–5 days
This step describes the culture of EECM-BMEC-like cells on collagen IV-coated plates before selec-
tive EC passage.
8. Seeding hPSC-derived EPCs for extended endothelial cell culture
a. Aspirate collagen IV coating solution from the 6-well plate. Add 1–2 3 105 purified CD31+
EPCs in 2 mL hECSR supplemented with 5 mM ROCK inhibitor Y-27632 (add ROCK inhibitor
stock solution at 1:2000) per well of the 6-well plate.
Note: Seeding density must be optimized for individual hPSC lines. We recommend seeding
CD31+ EPCs at a density such that CD31+ cells reach 100% confluency in 3–7 days.STAR Protocols 2, 100563, June 18, 2021
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forth and from side to side on the incubator shelf to evenly distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is impor-
tant to place the plate onto the incubator shelf first and move the plate using the shelf as sup-
port inside the incubator.
c. Approximately 24 h later, remove ROCK inhibitor by aspirating hECSR medium and replacing
with 2 mL fresh hECSR medium pre-warmed to 20C–25C.
d. Thereafter, change hECSRmedium every second day until CD31+ cells reach 100% confluency
(Figure 1)
Note: If the regular cell-feeding schedule cannot be accommodated over the weekend, we
recommend changing medium on Friday evening and again Monday early morning.
e. Once CD31+ cells reach 100% confluency, perform selective passaging as described below
(step 9).
CRITICAL: In general, waiting until CD31+ cells reach 100% confluency will lead to success-ful selective passage. However, for some hPSC lines, smooth muscle-like cells (SMLCs) also
detach if cultures are 100% confluent. In this case, we recommend attempting selective
passage with a less confluent (80% or less) culture.Timing: 3–5 days
After initial expansion of EPCs, resulting cultures typically contain both ECs and SMLCs. This step
describes a method to separate the two cell types and generate pure cultures of ECs (to establish
EECM-BMEC-like cells) and SMLCs (for preparation of SMLC-derived CM).
9. Selective EC passage to establish EECM-BMEC-like cells and SMLCs (Methods video S3)
a. Prepare a collagen IV-coated 6-well plate as described in step 7.
b. Aspirate hECSRmedium from 6-well plate containing CD31+ cells and add 1mL of Accutase to
each well of the 6-well plate.
c. Carefully monitor cell morphology under a microscope. Once ECs (but not non-ECs) appear
round (Figure 9, Methods video S3), tap the edge of the 6-well plate to detach ECs. After tap-
ping, many ECs should detach and non-ECs remain attached to the plate (Figure 9).Note: The procedure normally takes 2–5 min.
d. Collect detached ECs by avoiding resuspending non-ECs and transfer to a 15mL centrifuge
tube containing 4 mL of hESFM.
e. Add 2 mL hECSR medium to each well containing remaining attached non-ECs to obtain
smooth muscle-like cells (SMLCs). Return the plate to the incubator.
f. Resuspend the EC suspension in the 15 mL tube well and collect 10 mL of EC suspension for
counting.
g. Centrifuge ECs at 200 g, 5 min, at 20C–25C.
h. Aspirate supernatant and resuspend the pellet in 2 mL of hECSR medium per 1–2 3 105 ECs.
i. Aspirate collagen IV coating solution from the new 6-well plate. Add 2 mL EC suspension per
well.
j. Transfer 6-well plate into the incubator (37C, 5% CO2) and gently move the plate back and
forth and from side to side on the incubator shelf to evenly distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.STAR Protocols 2, 100563, June 18, 2021 17
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EC growth is shown in Figure 1).
Note: If the regular cell-feeding schedule cannot be accommodated over the weekend, we
recommend changing medium on Friday evening and again Monday early morning.
Note: Usually, 2–3 selective passages will yield nearly pure cultures of ECs (Figure 1), which
are ready for functional assays (steps 13–16). In general, we consider ECs at passages 3–5 as
EECM-BMEC-like cells. Proliferation typically slows after further passaging, however this is
variable between different hPSC lines.
Note: If selective passaging is unsuccessful, see troubleshooting problem 3.
l. For SMLC culture, change hECSR medium every other day (typical SMLC growth is shown in
Figure 1). To produce SMLC-conditioned medium (CM), instead of aspirating hECSR medium
when changing medium, collect hECSR medium and filter using a 0.22 mm filter. This CM can
be used for enhancing VCAM-1 expression on EECM-BMEC-like cells.
Note: We usually pool SMLC-CM until SMLCs reach 100% confluency.
Cryopreservation and thawing of EPCs, EECM-BMEC-like cells, or SMLCs
Timing: 30 min–1 h
After MACS, resulting EPCs can be cryopreserved for future use. Frozen EPCs can be used for
extended endothelial cell culture (step 8) after thawing (step 12). This step describes the method
of freezing EPCs.
10. Freezing EPCsa. Immediately after the last MACS wash (step 6 ‘‘q–s’’), resuspend the EPCs in freezingmedium
at a concentration of 1–2 3 106 cells per mL. Transfer 1 mL of EPCs suspension to each cry-
otube.
b. Transfer cryotubes to a controlled-rate freezing device and immediately place at 80C.
c. 24 to 48 h later transfer to liquid nitrogen tank for long-term storage.
Note: EPCs can be stored in liquid nitrogen for at least 2 years.
Timing: 30 min–1 h
After selective passage, resulting EECM-BMEC-like cells or SMLCs can be cryopreserved for future
use. Frozen EECM-BMEC-like cells and SMLCs are ready to use for quality control analyses (steps
13–16) after thawing (step 12). This step describes the method of freezing of EECM-BMEC-like cells
and SMLCs.
11. Freezing EECM-BMEC-like cells and SMLCs18a. Aspirate hECSR medium from 6-well plate containing EECM-BMEC-like cells or SMLCs and
add 1 mL of Accutase per well of a 6-well plate.
b. Incubate at 37C, 5% CO2 in the incubator until cells detach (approximately 7 min for EECM-
BMEC-like cells and 20–30 min for SMLCs).
c. Collect cells in a 15mL centrifuge tube containing 4mL of hESFM or DMEM/F-12-10 per 1mL
Accutase.
d. Resuspend EECM-BMEC-like cells or SMLCs suspension well and collect 10 mL of cell suspen-
sion for counting.STAR Protocols 2, 100563, June 18, 2021
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OPEN ACCESSProtocole. Centrifuge EECM-BMEC-like cells or SMLCs at 200 g, 5 min, at 20C–25C.
f. Aspirate supernatant and resuspend the EECM-BMEC-like cells or SMLCs pellet in freezing
medium at a cell number of 1–2 3 106 cells per mL. Transfer 1 mL of cell suspension to each
cryotube.
g. Transfer cryotubes to a controlled-rate freezing device and immediately place at 80C.
h. 24 to 48 h later transfer cryotubes to liquid nitrogen tank for long-term storage.
Note: EECM-BMEC-like cells and SMLCs can be stored in liquid nitrogen for at least 2 years.
Note: Fresh cultured EECM-BMEC-like cells and thawed EECM-BMEC-like cells show compa-
rable permeability values for sodium fluorescein and adhesion molecule phenotype.
CRITICAL: If EECM-BMEC-like cell proliferation is slow before freezing, EECM-BMEC-likecells may not form good confluent monolayers when cultivated on Transwell filters.Timing: 30 min–1 h
This step describes the method for thawing EPCs, EECM-BMEC-like cells and SMLCs.
12. Thawing EPCs, EECM-BMEC-like cells and SMLCsa. Prepare a collagen IV-coated 6-well plate as described in step 7.
b. Prepare a 15 mL Centrifuge tube containing 4 mL of hESFM or DMEM/F-12-10.
c. Thaw a cryotube containing EPCs, EECM-BMEC-like cells, or SMLCs rapidly rubbing the tube
between your hands it in your hand or swirling in a 37C water bath until there is only a small
piece of ice remaining.
d. Slowly add 500 mL of hESFM or DMEM/F-12-10 medium to the cryotube, and then transfer
the cell suspension to the centrifuge tube and resuspend.
e. Rinse the cryotube once with 1 mL hESFM or DMEM/F-12-10 and transfer to the centrifuge
tube.
f. Centrifuge cells at 200 g, 5 min, at 20C–25C.
g. Remove supernatant and resuspend the pellet in 2 mL hECSR medium supplemented with
5 mM ROCK inhibitor Y-27632 at a cell count of 2–3 3 105 cells. Add 2 mL cell suspension
to each well of a 6-well plate.
h. Transfer 6-well plate into the incubator (37C, 5% CO2) and gently move the plate back and
forth and from side to side on the incubator shelf to evenly distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.
i. One day later, remove ROCK inhibitor Y-27632 by replacing medium in each well with hECSR
medium.
Note: We recommend waiting until EECM-BMEC-like cells become 100% confluent before
starting functional assays and molecular characterization. EECM-BMEC-like cells typically
become 100% confluent at 2-3 days after thawing.
Quality control analyses of EECM-BMEC-like cells
Below, we provide protocols for quality control analyses of EECM-BMEC-like cells, including func-
tional assays for small molecule permeability and immune cell adhesion, and molecular assays for
key endothelial junctional and immune cell adhesion molecule expression. These quality control an-
alyses are critical to ensure that the differentiation has proceeded successfully and that EECM-
BMEC-like cells derived from different hPSC lines and in different laboratories are substantially
similar and have expected phenotypes.STAR Protocols 2, 100563, June 18, 2021 19
Table 1. Example of raw sodium fluorescein fluorescence intensity data measured on a plate reader and
permeability coefficient calculation
min filter_1 filter_2 filter_3 blank filter
15 79 88 93 1641
30 131 184 182 3246
45 212 232 202 3668
60 266 303 284 4529
60 (apical) 38564 37897 39005 32926
background 16 n/a n/a n/a
Subtract background (raw value - background) n/a n/a n/a n/a
15 63 72 77 1625
30 115 168 166 3230
45 196 216 186 3652
60 250 287 268 4513
60 (apical) 38548 37881 38989 32910
Correct signal (accounting for signal loss from sampling bottom well) n/a n/a n/a n/a
15 63 72 77 1625
30 121.3 175.2 173.7 3392.5
45 208.13 233.52 203.37 3991.25
60 270.813 310.352 288.337 4912.125
60 (apical) 38548 37881 38989 32910
Clearance volume at each time point (mL) n/a n/a n/a n/a
15 2.451 2.851 2.962 74.066
30 4.720 6.938 6.683 154.626
45 8.099 9.247 7.824 181.917
60 10.538 12.289 11.093 223.889
slope (mL/min) 0.184 0.204 0.170 3.178
Pe (mL/min) 0.196 0.218 0.180 n/a
Pe (103cm/min) 0.175 0.195 0.161 n/a
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OPEN ACCESS ProtocolTiming: 6 days for EECM-BMEC-like cell culture and 1.5–2 h for permeability assay
This step describes methodology for quality control of the diffusion barrier properties of EECM-
BMEC-like cells by performing a permeability assay for a small molecular tracer.
13. Measuring sodium fluorescein permeability (Methods video S4) (sample raw data and calcula-
tions are shown in Table 1 and expected results are shown in Figure 11)20a. Prepare 200 mL of 4:1:5 collagen IV/fibronectin/water coating solution (see materials and
equipment) per Transwell filter (PC Membrane, 0.4 mm, 12 mm, TC-Treated from Costar).
Add 200 mL to each Transwell filter and incubate in the incubator (37C, CO2 5%) for at least
4 h. We recommend incubating coated filters more than 8 h.
b. Aspirate hECSR medium from EECM-BMEC-like cells at passage 3–5 and add 1 mL of Accu-
tase per well of a 6-well plate.
c. Incubate at 37C, 5% CO2 in the incubator until EECM-BMEC-like cells detach (approxi-
mately 7 min).
d. Collect EECM-BMEC-like cells in a 15 mL centrifuge tube containing 4 mL of hESFM or
DMEM/F-12-10.
e. Resuspend EECM-BMEC-like cell suspension well and take 10 mL of cell suspension for
counting.
f. Centrifuge EECM-BMEC-like cells at 200 g, 5 min, at 20C–25C.
g. Aspirate supernatant and resuspend the EECM-BMEC-like cell pellet in 500 mL hECSR me-
dium with a cell count of 1.123 105 cells. Aspirate the collagen IV/fibronectin/water coatingSTAR Protocols 2, 100563, June 18, 2021
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each Transwell filter. Add 1.5 mL of hECSR medium to the bottom chamber.
Note: We recommend preparing triplicate Transwell filters for measurement and one blank
filter without cells.
h. Transfer 6-well plate into the incubator (37C, 5% CO2) and gently move the plate back and
forth and from side to side on the incubator shelf to evenly distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.
i. Thereafter change hECSR medium every second day until day 6.
j. At day 6, prepare a new 12-well plate containing 1.5 mL warm hECSR medium per well. Use
forceps to carefully transfer the Transwell filters intended for permeability assay (including
the blank Transwell filter) to this new 12-well plate.
k. In a 15 mL centrifuge tube, prepare 500 mL of 10 uM sodium fluorescein solution in hECSR
medium (add sodium fluorescein stock solution at 1:1000) per Transwell filter (including
the blank Transwell filters).
l. Remove hECSRmedium from the top chamber and replace with 500 mL hECSR medium con-
taining 10 mM sodium fluorescein in all samples (including the blank Transwell filters).
m. At 15, 30, 45, and 60 min, collect 150 mL of medium from the bottom chamber of each Trans-
well and place into a 96-well plate (flat bottom). Go into the bottom chamber at the side of
the filter and pipette gently up and down 2–3 times with micropipette before extracting
150 mL. Replace the missing volume with 150 mL pre-warmed hECSR medium into the bot-
tom chamber.
n. At the 60-minute time point, also collect 150 mL of medium from the top chamber of each
Transwell and transfer to a 96-well plate.
o. Place an additional 150 mL of hECSR medium without sodium fluorescein in the 96-well plate
for background subtraction.
Note: Samples from the top chambers may need to be diluted to prevent an oversaturated
signal.
p. Read the fluorescence intensity using a fluorescent plate reader (485 nm excitation/530 nm
emission) (example of raw data measured on a plate reader and example of Pe calculation is
found in Table 1).
q. Correct the signal by removing background and accounting for signal loss from sampling the
bottom chamber. For example, after subtracting the background, the 15-minute sample
exhibits a signal of 1000 relative fluorescence units (RFU) and the 30-minute
sample exhibits a signal of 1500 RFU. The corrected signal at 30 min is (1500 RFU + (1000
RFU3 150 mL/1500 mL)) = 1500 RFU + 100 RFU = 1600 RFU. When calculating the 45 minute
corrected value, use 1600 RFU as the 30-minute sample value.
r. Calculate the clearance volume at each time point (Coisne et al., 2005; Cecchelli et al.,
2014).
Clearance volume = (V B 3 (SB,t)) / (ST, 60 min), where VB is the volume of bottom chamber
(1500 mL); SB,t is the corrected signal of the bottom chamber at time, t; ST,60 min is the signal
of top chamber at 60 min.
s. Calculate the linear slope of clearance volume vs. time using linear regression for each of the
triplicate culture Transwell filters (mc) and the blank filter (mf).
t. Calculate sodium fluorescein permeability for each of the triplicate culture Transwell filters
by subtracting the ‘‘resistance’’ of the blank Transwell filter (reciprocal slope of clearance vol-
ume vs. time) from the ‘‘resistance’’ of the cell-containing Transwell filter using the following
formula: 1/Pe = 1/mc-1/mf.STAR Protocols 2, 100563, June 18, 2021 21
Figure 3. Immunofluorescence staining of EECM-BMEC-like cells grown on 0.4 mm pore Transwell filters for 6 days
VE-cadherin (red), claudin-5 (red), occludin (red), and nuclei (DAPI; blue) are shown. Staining was performed after
permeability assays. Scale bar = 50 mm.
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OPEN ACCESS Protocolu. The slope of reciprocal clearance volume vs. time should have units min/mL; to convert to
typical units, use the area of the Transwell filter (1.12 cm2): Pe [cm/min] = (1/Pe)–1 [mL/min]
/ (1000 mL/cm3 3 1.12 cm2).
Note: After the permeability assay, Transwell filters can be fixed with 20C precooled meth-
anol (150 mL top chamber/1 mL bottom chamber) for 20 s. After rehydrating and washing, cut
filters out using a scalpel (Methods video S5), transfer to a 24-well plate and add 150 mL of
blocking buffer for blocking and cell membrane permeabilization. Then stain for junctional
molecules to evaluatemonolayer confluency as described below. After staining, transfer filters
to a glass slide, mount with Mowiol, and coverslip.
Timing: 2 days (24-well plate) or 6 days (Transwell filter) for cell culture and 2–3 h for immu-
nofluorescence staining
This step describes immunofluorescence staining methods for quality control of EECM-BMEC-like
cells and SMLCs. Specifically, EECM-BMEC-like cells are stained for junctional proteins to confirm
maturation of cell-cell junctions, and for key endothelial adhesion molecules. SMLCs are stained
for key components of smooth muscle cell contractile machinery.
14. Immunofluorescence staining of EECM-BMEC-like cell monolayers and SMLCs (expected re-
sults are shown in Figures 3, 4, and 5)
Note: Immunofluorescence staining can be performed on chamber slides, 96-well plates, or
Transwell filters. We here describe the method for EECM-BMEC-like cells or SMLCs cultured
on 16-well chamber slides or 96-well plates. For cultivation of EECM-BMEC-like cells on Trans-
well filters, see step ‘‘13’’.22a. Prepare collagen IV-coated chamber slides or 96-well plates as described in step 7, except
use a volume of 60 mL of coating solution per well of a 16-well chamber slide or 96-well
plate.
b. Aspirate hECSR medium from the 6-well plate containing EECM-BMEC-like cells or SMLCs
and add 1 mL of Accutase per well of the 6-well plate.
c. Incubate at 37C, 5% CO2 in the incubator until cells detach (approximately 7 min for EECM-
BMEC-like cells and 10–20 min for SMLCs).
d. Collect EECM-BMEC-like cells or SMLCs in a 15 mL centrifuge tube containing 4 mL of
hESFM or DMEM/F-12-10 per 1 mL of Accutase.
e. Resuspend EECM-BMEC-like cells or SMLCs suspension well and take 10 mL of cell suspen-
sion for counting.
f. Centrifuge EECM-BMEC-like cells or SMLCs at 200 g, 5 min, at 20C–25C.
g. Aspirate supernatant and resuspend at 2.53 105 EECM-BMEC-like cells or SMLCs per mL of
hECSR medium. Aspirate the collagen IV coating solution and add 100 mL of EECM-BMEC-
like cells or SMLCs suspension to each well of the 16-well chamberslide or 96-well plate
(2.5 3 104/well).STAR Protocols 2, 100563, June 18, 2021
Figure 4. Immunofluorescence staining of SMLCs grown on chamberslide
a-SMA (red), SM22a (red), calponin (red), and nuclei (DAPI; blue) are shown. Scale bar = 50 mm.
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OPEN ACCESSProtocolh. Transfer 16-well chamber slide or 96-well plate into the incubator (37C, 5% CO2) and gently
move the plate back and forth and from side to side on the incubator shelf to evenly
distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.
i. Once EECM-BMEC-like cells or SMLCs attach to the slide or plate (1–2 h later), replace
hECSR medium with 100 mL hECSR medium and remove nonadherent EECM-BMEC-like
cells or SMLCs.
j. Approximately 24 h later, change hECSRmedium again for feeding. To investigate adhesion
molecule expression on EECM-BMEC-like cells, change hECSR medium to CM derived from
SMLCs (for preparation of CM, see step ‘‘9l’’) in the presence or absence of 0.1 ng/mL TNF-
a + 2 IU/mL IFN-g for 16–24 h.
k. The primary antibody staining procedure depends on the target antigen (see key resources
table: Antibodies used for immunofluorescence staining, for suggested antibody dilutions).
i. To stain for junctional molecules (e.g., claudin-5, occludin, VE-cadherin), fix EECM-
BMEC-like cells with 100 mL of 20C precooled methanol for 20 s and rehydrate by
washing 3 times with 100 mL of dPBS. Block and permeabilize cell membrane with
100 mL of blocking buffer for 10 min at 20C–25C, and then stain with 100 mL of primary
antibodies diluted in blocking buffer for 1 h at 20C–25C.
Note: Although paraformaldehyde fixation permits detection of some junctional molecules
(e.g., VE-cadherin), methanol fixation is superior in maintaining epitopes of tight junction
molecules (e.g., claudin-5 and occludin).
ii. To stain for adhesionmolecules ICAM-1 and VCAM-1, dilute primary antibodies in 100 mL
of hECSR medium, add to live EECM-BMEC-like cells, and incubate at 37C, 5% CO2 in
the incubator for 15 min. Live cell-labeling allows for selective detection of cell surface-
expressed adhesion molecules, which are functionally available for immune cell interac-
tion. After washing with dPBS, fix EECM-BMEC-like cells with 100 mL of 1% (w/v) parafor-
maldehyde in dPBS for 10 min at 20C–25C. Wash cells with dPBS and block EECM-
BMEC-like cells with 100 mL of blocking buffer for 10 min at 20C–25C.
iii. To stain for asmooth muscle actin, calponin, and SM22a, fix SMLCs with 100 mL of 1%
(w/v) paraformaldehyde in dPBS for 10 min at 20C–25C. After washing with 100 mL of
dPBS, block and permeabilize SMLCs with 100 mL of blocking buffer for 10 min at
20C–25C. Then incubate SMLCs with 100 mL of primary antibodies diluted in blocking
buffer for 1 h at 20C–25C.
l. Wash EECM-BMEC-like cells or SMLCs three times with 100 mL of dPBS and incubate with
100 mL of secondary antibodies diluted in blocking buffer (see key resources table: Anti-
bodies used for immunofluorescence staining, for appropriate secondary antibodies and
suggested concentrations) for 1 h at 20C–25C. Add DAPI at 1 mg/mL or Hoechst 33342
at 4 mM to secondary antibody solutions to stain the cell nuclei.STAR Protocols 2, 100563, June 18, 2021 23
Figure 5. Immunofluorescence staining of EECM-BMEC-like cells grown on 0.4 mm pore Transwell filters in the
presence of SMLC-derived CM
ICAM-1 (red), VCAM-1 (red), and nuclei (DAPI; blue) are shown for non-stimulated and inflammatory cytokine-
stimulated (1 ng/mL TNF-a + 20 IU/mL IFN-g) conditions. Scale bar = 50 mm.
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OPEN ACCESS Protocolm. Wash EECM-BMEC-like cells or SMLCs three times with 100 mL of dPBS. If using a chamber
slide, remove plastic chamber from the glass slide, mount with Mowiol, and coverslip.
n. Examine slide/plate under a fluorescence microscope.
Timing: 2 days (24-well plate) or 6 days (Transwell filter) for EECM-BMEC-like cell culture
and 2–3 h for flow cytometry assay
This step describes a flow cytometry-based method for quality control of the adhesion molecule
phenotype of EECM-BMEC-like cells. This assay is especially important to ensure expression of a
panel of endothelial adhesion molecules, which is a unique and characteristic feature of EECM-
BMEC-like cells when compared to other hPSC-derived blood-brain barrier (BBB) models.
15. Flow cytometry analysis of adhesion molecule expression of EECM-BMEC-like cells (Expected
results are shown in Figure 6)
Note: Flow cytometry analysis can be performed on EECM-BMEC-like cells cultured in 24-well
plates or Transwell filters. We describe here the method of EECM-BMEC-like cells cultured on
24-well plates. For the cultivation of EECM-BMEC-like cells on Transwell filters, see step ‘‘13’’.24a. Prepare a collagen IV-coated 24-well plate as described in step 7, except use a volume of
300 mL of coating solution per well of 24-well plate.
b. Aspirate hECSR medium from 6-well plate containing EECM-BMEC-like cells and add 1 mL
of Accutase per well of the 6-well plate.
c. Incubate at 37C, 5% CO2 in the incubator until EECM-BMEC-like cells detach (approxi-
mately 7 min).
d. Collect EECM-BMEC-like cells in a 15 mL centrifuge tube containing 4 mL of hESFM or
DMEM/F-12-10 per 1 mL of Accutase.STAR Protocols 2, 100563, June 18, 2021
Figure 6. Flow cytometry analysis of EECM-BMEC-like cells grown on 24-well plate in the presence of SMLC-derived CM for adhesion molecules
Isotype control, non-stimulated (NS) and 16 h pro-inflammatory cytokine-stimulated condition (stim, 1 ng/mL TNF-a + 20 IU/mL IFN-g) are represented
respectively in gray, blue, and red lines in a histogram overlay.
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OPEN ACCESSProtocole. Resuspend EECM-BMEC-like cells suspension well and collect 10 mL of cell suspension for
counting.
f. Centrifuge EECM-BMEC-like cells at 200 g, 5 min, at 20C–25C.
g. Aspirate supernatant and resuspend at 9.5 3 104 EECM-BMEC-like cells per ml of hECSR
medium. Aspirate the collagen IV coating solution and add 1 mL of EECM-BMEC-like cells
suspension to each well of the collagen IV-coated 24-well plate (9.5 3 104/well).
Note: Seed EECM-BMEC-like cells onto at least 2 wells of 24-well plate for non-stimulated
and pro-inflammatory cytokine-stimulated conditions.
h. Transfer 24-well chamber slide or 96-well plate into the incubator (37C, 5% CO2) and gently
move the plate back and forth and from side to side on the incubator shelf to evenly
distribute the cells.
Note: Avoid circular motions to prevent cells from pooling in the center of the well. It is
important to place the plate onto the incubator shelf first and move the plate using the shelf
as support inside the incubator.
i. Approximately 24 h later, change hECSR medium to CM derived from SMLCs (for prepara-
tion of CM, see step ‘‘9l’’) in the presence or absence of 1 ng/mL TNF-a + 20 IU/mL IFN-g for
16–24 h.
j. After pro-inflammatory cytokine stimulation, aspirate CM from 24-well plate containing
EECM-BMEC-like cells and add 200 mL of Accutase per well of the 24-well plate. Incubate




Protocolk. Collect EECM-BMEC-like cells in 15 mL centrifuge tubes containing 4 mL of hESFM or
DMEM/F-12-10.
l. Resuspend EECM-BMEC-like cells suspension well and collect 10 mL of cell suspension for
counting.
m. Centrifuge EECM-BMEC-like cells at 200 g, 5 min, at 20C–25C.
n. Aspirate supernatant and resuspend at 1 3 106 EECM-BMEC-like cells per ml of FACS
buffer. Add 100 mL of EECM-BMEC-like cell suspension to each well of a 96-well plate (round
bottom) (1 3 105/well).
Note: We recommend preparing 3 wells (unstained control, isotype control mixture, adhe-
sion molecules staining mixture)/sample (non-stimulated and pro-inflammatory cytokine
stimulated condition).
o. Centrifuge EECM-BMEC-like cells in the 96-well round bottom plate at 330 g, 3 min, at 4C.
CRITICAL: From now on, maintain EECM-BMEC-like cells at 4C to avoid antibody
internalization.p. Prepare adhesion molecule antibody staining mixture, and isotype control antibody mixture
solutions in FACS buffer (total volume 100mL/sample) (see key resources table: Antibodies
used for flow cytometry analysis).
q. Discard buffer by inverting the 96-well plate in one quick forceful shake of motion and then
resuspend EECM-BMEC-like cells in 100 mL of prepared antibody solutions (adhesion mol-
ecules staining mixture and isotype control antibody mixture) or FACS buffer for the un-
stained control. Stain EECM-BMEC-like cells with fluorescent labeled antibodies at 4C
for 20 min.
Note: After centrifugation, cell pellets remain sufficiently attached to the bottom of the 96-
well plate. A single quick and forceful shake of the inverted 96-well plate discards the super-
natant and avoids any cell loss.
r. Prepare compensation beads for compensation. Add 1 drop of positive beads and negative
beads into 2 mL of FACS buffer and aliquot compensation beads suspensions into 7 sepa-
rate flow tubes, then add respective volume (see key resources table: Antibodies used for
flow cytometry analysis) of each fluorophore-conjugated antibody (see key resources table:
Antibodies used for flow cytometry analysis). Store at 4C protected from light until the mea-
surement.
Note: We recommend using antibody compensation beads for single antibody staining for
compensation since EECM-BMEC-like cells do not necessarily contain both negative and
positive cells for all antigens of interest.
s. After 20 min of antibody incubation, centrifuge EECM-BMEC-like cells at 330 g, 3 min, at
4C.
t. Discard buffer containing antibodies by inverting the 96-well plate in one continuous motion
and add 200 mL of FACS buffer and resuspend EECM-BMEC-like cells for washing.
Note: After centrifugation, cell pellets remain sufficiently attached to the bottom of the 96-
well plate. A single quick and forceful shake of the inverted 96-well plate discards the super-
natant and avoids any cell loss.
u. Centrifuge EECM-BMEC-like cells at 330 g, 3 min, at 4C.
v. Discard buffer by inverting the 96-well plate in one continuous motion.
Note: After centrifugation, cell pellets remain sufficiently attached to the bottom of the 96-
well plate. A single quick and forceful shake of the inverted 96-well plate discards the super-
natant and avoids any cell loss.
w. Resuspend EECM-BMEC-like cells in 200 mL of FACS buffer and analyze on a flow cytometer.STAR Protocols 2, 100563, June 18, 2021
Figure 7. Adhesion assay using EECM-BMEC-like cells with T cells
The number of cell tracker-labeled T cells adherent to non-
stimulated (NS) and 0.1 ng/mL TNF-a + 2 IU/mL IFN-g stimulated
EECM-BMEC-like cell monolayers were shown. Bars show the
mean, and error bars show SD. Statistical analysis: unpaired t test.
(P< 0.001 = ***).
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OPEN ACCESSProtocolNote:We use the Attune NxT Flow Cytometer (Thermofisher Scientific) and the following set-
tings: FSC (voltage 50), SSC (voltage 280), BL1 filter (voltage 300) for FITC detection, RL1 filter
(voltage 360) for APC detection, RL3 filter (voltage 340) for APC-Cy7 detection, VL1 filter
(voltage 220) for BV421 detection, VL2 filter (voltage 240) for BV510 detection, YL1 filter
(voltage 320) for PE detection, and YL4 filter (voltage 340) for PE-Cy7 detection.
Timing: 2 days for EECM-BMEC-like cells culture and 3–4 h for T-cell adhesion assay
This step describes a T-cell adhesion assay under static conditions to assess functional expression of
endothelial adhesion molecules on EECM-BMEC-like cells. This assay is especially important since
EECM-BMEC-like cells with their mature immune phenotype are the first hPSC-derived BBB model
suitable to study immune cell interactions.
16. T-cell adhesion assay under static condition (expected results are shown in Figure 7)
Note: We here describe the method using human Th1 cells sorted from peripheral blood
based on their chemokine receptor expression and expanded for 20 days with periodic restim-
ulation with phytohemagglutinin and irradiated allogeneic peripheral blood mononuclear
cells and human IL-2 exactly as described before (Nishihara et al., 2020a, 2020b; Sallusto
et al., 1998; Engen et al., 2014). The T-cell culture medium and number of T cells added to
EECM-BMEC-like cells needs to be optimized for the T cells of your interest.a. Prepare EECM-BMEC-like cell monolayers as described in section 14 steps ‘‘a–i’’.
Note: We usually prepare at least 8 wells (4 wells for non-stimulated and 4 wells for pro-in-
flammatory cytokine-stimulated conditions).
b. Approximately 24 h later, change hECSR medium to CM derived from SMLCs (for prepara-
tion of CM, see step ‘‘9l’’) in the presence or absence of 0.1 ng/mL TNF-a + 2 IU/mL IFN-g for
16–24 h.
c. Prepare a 15 mL centrifuge tube containing 10 mL T-cell wash buffer at 37C.
d. Thaw 1 vial (8 3106 cells) of cryopreserved T cells by rapidly rubbing the tube between your
hands or swirling in a 37C water bath until there is only a small piece of ice remaining.
e. Using a micropipette, carefully drop the cell suspension into the 15 mL centrifuge tube con-
taining 10 mL T-cell wash buffer.
Note: At the first signs of thawing, T cells should immediately be transferred into the 15 mL
tube containing 10 mL of T-cell wash buffer to reduce cryopreservation-mediated damage to
the cell membranes.
f. Centrifuge T cells at 280 g, 5 min, at 20C–25C. While T cells are centrifuging, label a 24-
well plate with the name of the T cell and date.
g. Remove the supernatant and carefully resuspend the pellet in 2 mL of T-cell medium and
seed the T cells suspension onto 2 wells of 24-well plate.




Protocoli. At the day of the experiment, label T cells with 1 mM CMFDA (add CMFDA stock solution at
1:3000) at 37C, 5% CO2 in the incubator for 30 min.
j. After CMFDA labeling, collect T cells into 15 mL centrifuge tube and fill up to 12 mL with T-
cell wash buffer.
k. Centrifuge T cells at 280 g, 5 min, at 20C–25C.
l. Aspirate supernatant and resuspend T cells in 6 mL of T-cell wash buffer.
m. Carefully add 3 mL of Ficoll-Paque PLUS below the T cell suspension.
n. Centrifuge at 770 g, 20 min at 20C–25C with minimum brake and acceleration.
o. Using micropipette, collect live T cell interphase between the T-cell wash buffer and the Fi-
coll-Paque PLUS into a new 15 mL centrifuge tube and fill to 12 mL using T-cell wash buffer.
Note: For the details on usage of Ficoll-Paque PLUS, please refer to the manufacturer’s instruc-
tions https://www.sigmaaldrich.com/technical-documents/protocols/biology/isolation-of-mono
nuclear-cells/recommended-standard-method.html
p. Centrifuge T cells at 280 g, 5 min, at 20C–25C.
q. Aspirate supernatant and resuspend T cells in 5 mL of migration assay medium.
r. Resuspend T cell suspension well and take 10 mL of cell suspension for counting.
s. Centrifuge T cells at 280 g, 5 min, at 20C–25C.
t. Aspirate supernatant and resuspend at 2 3 105 T cells per ml of migration assay medium.
u. Carefully remove CM from chamber slide containing EECM-BMEC-like cells and add 100 mL
of T cell suspension (2.0 3 104 cells/well).
CRITICAL:We recommend not washing the EECM-BMEC-like cell monolayer before add-ing the T cells to avoid disruption of the EECM-BMEC-like cell monolayer.v. Incubate EECM-BMEC-like cells with T cells on an orbital shaker platform for 30 min at 20C–
25C with protection from light.
w. After 30 min of T cell-EECM-BMEC-like cell interaction, remove plastic chambers from the
glass slide.
x. Wash the slide containing T cell and EECM-BMEC-like cells twice by gently dipping the slide
into a jar with dPBS to remove non-adherent T cells.
y. Fix adherent T cell and EECM-BMEC-like cells with 2.5% (v/v) glutaraldehyde solution
diluted in dPBS at 4C for 2 h.
Note: We recommend using glutaraldehyde solution to fix cells after the adhesion assay
since glutaraldehyde is a stronger fixative compared to paraformaldehyde and thus reduces
the risk of T cells detaching from the EECM-BMEC-like cells.
z. After 2 h of fixation, wash slides containing adherent T cells and EECM-BMEC-like cells twice
by dipping into a jar with dPBS and examine the slide using a fluorescence microscope.Note: We image adherent T cells using the 10 3 objective of the fluorescence microscope Nikon
Eclipse E600 microscope connected to a Nikon Digital Camera DXM1200F with Nikon NIS-Elements
BR3.10 software (Nikon, Egg, Switzerland). Acquire images from the center of the well. Analyze im-
ages with FIJI software (Version 2.0.0, Image J, USA) using following macro (Threshold and particle
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Figure 8. Image of EPC differentiation at day 4
(A) Optimal seeding density produces a confluent monolayer of differentiating cells.
(B) A seeding density that is too high results in differentiating cells detaching from plate surface.
ll
OPEN ACCESSProtocolrun("Convert to Mask");
run("Watershed");
run("Analyze Particles...", "size=50-Infinity circularity=0.1-1.00 show=Overlay summarize")
EXPECTED OUTCOMES
The anticipated outcomes of this protocol are as follows:
EPC differentiation
EPC differentiation should yield a population of 10%–40% CD31+ EPCs pre-MACS and ideally >95%
EPCs post-MACS (Figure 2).
Permeability assay
The typical permeability coefficient of EECM-BMEC-like cell monolayers measured for sodium fluo-
rescein is below 0.5 3 103 cm/min.
Immunocytochemistry staining of EECM-BMEC-like cells after permeability assay
After selective passages (EECM-BMEC-like cells at passage 3–5), EECM-BMEC-like cells should form
monolayers without any remaining SMLCs and display continuous tight and adherens junctions
(Figure 3).
Immunocytochemistry staining of SMLCs cultivated on a chamber slide
SMLCs should stain positive for a-SMA, SM22a, and calponin (Figure 4).
Staining of EECM-BMEC-like cells for adhesion molecules by immunofluorescence staining and
flow cytometry
EECM-BMEC-like cells co-cultured with SMLC or cultivated using SMLC-derived CM should stain
positive for ICAM-1 under both non-stimulated and proinflammatory cytokine-stimulated conditions
as well as for VCAM-1 after proinflammatory cytokine stimulation (Figures 5 and 6).
T-cell adhesion on EECM-BMEC-like cells under static condition
Pro-inflammatory cytokine stimulation significantly increases the numbers of T cells adhering to
EECM-BMEC-like cell monolayers (Figure 7).
LIMITATIONS
This protocol has been tested with H9 hESCs, IMR90-4 hiPSCs, six healthy control-derived hiPSC
lines (Nishihara et al., 2020a) and seven patient derived hiPSC lines (Perriot et al., 2018). However,STAR Protocols 2, 100563, June 18, 2021 29
Figure 9. Bright field images of ECs during selective passage
Red arrows indicate detachment of SMLCs within SMLCs island. Scale bar = 100 mm.
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OPEN ACCESS Protocolthe efficiency of the protocol may vary with other hPSC lines andmay require adjustment of the initial
seeding density and CHIR99021 concentrations.TROUBLESHOOTING
Problem 1: Differentiating cell detachment during EPC differentiation
Differentiating cell detachment is usually observed at day 3 - day 5 of EPC differentiation (Figure 8).Potential solution
If differentiating cells detach from the surface, decrease the initial hPSC seeding density. We recom-
mend testing different seeding densities at day -3 (range from 20–1003103/cm2 or 75–4003103 per
well of a 12-well plate). Optimize seeding density for individual hPSC lines and passages. Alterna-
tively, optimization of the CHIR99021 concentration may be required. Though we identified 7–
8 mM CHIR99021 to be optimal for the hPSC lines tested by us, other lines may respond to
CHIR99021 treatment differently.Problem 2: Low EPC purity
Low EPC purity is observed when differentiating hPSCs towards EPCs.Potential solution
If EPC purity of a pre-MACS sample is less than 10% CD31+ cells, optimize the initial hPSC seeding
density. Typically, increasing seeding density results in a higher EPC percentage. However, seeding
densities that are too high often lead to ‘‘Problem 1’’ (cell detachment). We recommend testing
different seeding densities at day -3 (range from 20–100 3 103/cm2 or 75–400 3103 per well of a
12-well plate) and optimizing seeding density for individual lines and passages. A successful differ-
entiation can often be predicted by monitoring key features of the differentiating cells as follows:
Differentiating cells should be confluent by day 1, or at the latest day 2. Similarly, the medium color
should be nearly yellow prior to medium change on day 2 – day 5. If the color is red – orange (Fig-
ure 1), differentiation is likely to fail.30 STAR Protocols 2, 100563, June 18, 2021
Figure 10. Bright field images of post-MACS EPCs in the presence or absence of 10 ng/mL VEGF supplementation
Scale Bars = 100 mm.
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OPEN ACCESSProtocolProblem 3: Failure of selective EC passage
Failure of selective passage is usually observed if the proportion of SMLCs in a culture is high (more
than approximately 30%) when passaging ECs.Potential solution
A critical parameter for a successful selective passage is the percentage of SMLCs in the culture,
which should ideally be less than 10%. At more than 30% SMLCs, a successful selective passage is
quite difficult (Figure 9). If EPC purity of the post-MACS sorting sample is less than 90% CD31+,
the population of non-ECs will increase over time. In this case, we recommend optimizing the initial
hPSC seeding density to improve pre-MACS purity (see problem 2) and/or exercising additional care
during MACS to remove non-bound cells (see step ‘‘6q’’ and Methods video S2).
A successful selective passage is typically achieved when cells are 100% confluent and SMLCs form
clear islands (Figure 1). However, for some hPSC lines, SMLCs also detach if cultures are 100%
confluent. In this case, we recommend attempting selective passage with a less confluent (80% or
less) culture.
Alternatively, we have found that adding VEGF at 10 ng/mL to hESCR medium during the first 3–
5 days of EC culture (starting immediately after MACS and until cells reach 100% confluency) facil-
itates rapid proliferation of ECs (Figure 10). The resulting EECM-BMEC-like cells at passage 3–5
show comparable permeability values to non-VEGF-treated cells (Figure 11).Figure 11. Permeability to sodium fluorescein of EECM-BMEC-
like cells pretreated with 10 ng/mL VEGF for 3–5 days
immediately after MACS compared to non-VEGF-treated cells
Bars show the mean, and error bars show SD.
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Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Britta Engelhardt (bengel@tki.unibe.ch).
Materials availability
This study did not generate new unique reagents and the majority of materials required in this pro-
tocol are commercially available. The iPS(IMR90)-4 iPSC line and H9 (WA09) hESC line can be ob-
tained from WiCell (https://www.wicell.org) upon completion of a material transfer agreement.
Data and code availability
This study did not generate/analyze any datasets or code that were submitted to any repositories.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.xpro.2021.100563.
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